



Atty. Dkt. No. 072121-0389
(16325.009)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Paul A. RENHOWE et al.
Title: HETEROCYCLIC COMPOUNDS
Appl. No.: 10/823,995
Filing Date: April 14, 2004
Examiner: Unknown
Art Unit: Unknown

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.

Bernard P. Friedrichsen

(Printed Name)

(Signature)

January 12, 2005

(Date of Deposit)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR § 1.97(b)(3), before the mailing date of the first Office Action on the merits. In the event that an Office Action on the merits has been mailed to applicants, then the listed documents are being submitted in compliance with 37 CFR § 1.97(c)(2), and the Commissioner is hereby authorized to charge the fee of \$180.00 (Fee Code 1806) set forth in 37 CFR § 1.97(c)(2) and § 1.17(p) to Deposit Account No. 50-2350 for such purpose. The fee is not to be charged to the Deposit Account unless an Office Action on the merits has been mailed to Applicants. The listed documents were cited in a Notice of References Cited for a related United States patent application (USSN 10/116,117) along with an Office Action dated December 15, 2004.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-2350. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-2350.

Respectfully submitted,

Date January 12, 2005

By 

FOLEY & LARDNER LLP
Customer Number: 27476
Telephone: (608) 258-4281
Facsimile: (608) 258-4258

Bernard P. Friedrichsen
Attorney for Applicant
Registration No. 44,689



Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 072121-0389		SERIAL NO. 10/823,995		
INFORMATION DISCLOSURE CITATION Date Submitted: January 12, 2005 (Use several sheets if necessary)				APPLICANT Renhowe et al.				
				FILING DATE 04/14/2004		GROUP ART UNIT Unknown		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
		Salmon, S. E. et al., <i>Basic & Clinical Pharmacology, Seventh Edition</i> , edited by B. Katzung, Appleton & Lange, pp. 29, 881-884 (1998).						
		Milauer, B. et al., "Glioblastoma Growth Inhibited In Vivo by a Dominant-Negative Flk-1 Mutant," <i>Nature</i> , Vol. 367, pp. 576-579 (1994); published by Nature Publishing Group.						
		Pinedo, H. M. et al., "Translational Research: The Role of VEGF in Tumor Angiogenesis," <i>The Oncologist</i> 2000, Vol. 5 (suppl. 1), pp. 1-2 (2000).						
		McMahon, G., "VEGF Receptor Signaling in Tumor Angiogenesis," <i>The Oncologist</i> 2000, Vol. 5 (suppl. 1), pp. 3-10 (2000).						
EXAMINER				DATE CONSIDERED				
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.								